In a groundbreaking study, Dr. Marcus Sucksdorff's doctoral research at the field of neurology has revealed the potential of PET imaging in predicting the progression of Multiple Sclerosis (MS) and assessing treatment response. This innovation could also serve as a biomarker in the development of drugs targeted at progressive MS in the future.
MS, an inflammatory autoimmune disease that degenerates the central nervous system, is the most common such condition among young adults.